Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Below 200 Day Moving Average - Here's What Happened

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $9.03 and traded as low as $7.76. Ocular Therapeutix shares last traded at $7.89, with a volume of 929,749 shares.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Scotiabank began coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average target price of $16.71.

Ocular Therapeutix Stock Down 1.4 %

The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -5.83 and a beta of 1.23. The firm's fifty day moving average price is $8.70 and its two-hundred day moving average price is $9.01. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the company's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ocular Therapeutix

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. bought a new position in Ocular Therapeutix in the 3rd quarter valued at about $24,584,000. Deltec Asset Management LLC boosted its position in shares of Ocular Therapeutix by 0.6% during the fourth quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock valued at $22,344,000 after buying an additional 16,300 shares during the last quarter. Braidwell LP boosted its position in shares of Ocular Therapeutix by 36.3% during the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company's stock valued at $19,486,000 after buying an additional 596,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company's stock valued at $9,661,000 after buying an additional 660,080 shares during the last quarter. Finally, Rosalind Advisors Inc. grew its holdings in Ocular Therapeutix by 18.0% during the third quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company's stock worth $7,700,000 after buying an additional 135,000 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.